Welcome, Guest. Please login or register.
September 26, 2022, 02:11:41 AM
Home Help Search Login Register
News: Ceriatone Forums are up and running!!!
 
Guests please register
Note: If you want to help you can donate to keep the forums alive.










Do you want to advertise on this forum ? Send me a private message.



Amplified Parts
+  Ceriatone Forum
|-+  Website, Store
| |-+  Ceriatone.com
| | |-+  The viral vector, non-viral vector and gene therapy manufacturing market
« previous next »
Pages: [1] Go Down Print
Author Topic: The viral vector, non-viral vector and gene therapy manufacturing market  (Read 34 times)
jameshebrew
Newbie
*
Offline Offline

Posts: 43


View Profile
« on: September 22, 2022, 03:13:52 AM »

Rise in clinical research activity for genetically modified therapies has resulted in the increase in demand for vectors, offering lucrative opportunities to players having capabilities for in-house and contract manufacturing of various types of vectors.

Roots Analysis has announced the addition of “Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings.

The viral vector manufacturing and non-viral vector manufacturing landscape features a mix of industry players (well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes. Over the past few years, cell and gene therapies have gained significant popularity owing to their therapeutic potential. In fact, more than 20 genetically modified therapies have already been approved, which has resulted in the increase in demand for vectors, which have proven to be highly efficient for the delivery of genetic material to the targeted area. In order to cater to the growing demand, several companies are offering diverse range of services for vector and gene therapy manufacturing. 

To request a sample copy / brochure of this report, please visit link
https://www.rootsanalysis.com/reports/274/request-sample.html

Key Market Insights

More than 140 stakeholders claim to manufacture viral and non-viral vectors
The market is currently dominated by the presence of various mid-sized industry players (50%); of these 57% of players are contract manufacturers, whereas 22% of players are in-house manufacturers.

Over the time, several advancements have been made for the development of vector based technological platforms
Majority (37%) of the available technologies are currently used in vector manufacturing followed by those available for manufacturing of cell and gene therapies (16%). Further, 53% of the vector-based technologies are dedicated for the development and manufacturing of adenoviral vectors.

More than 295 partnerships were established between different stakeholders during the last decade
Close to 55% partnerships have been reported post 2018, wherein, maximum partnerships were recorded in year 2022 (till May). Further, maximum partnerships were related to manufacturing (23%) followed by licensing agreement (20%) and product development agreement (15%).

Close to 120 expansion activities have been recorded till 2022, growing at a CAGR of 10%
Majority of the expansions in this domain were related to the establishment of new facility (39%) followed by facility expansion (12%).

The installed vector manufacturing capacity is estimated to be ~186,150 L
Majority (70%) of total installed capacity is currently available for clinical / commercial stage manufacturing of viral vectors. Further, players headquartered in North America (56%) have the highest installed capacity, across the globe.

Till 2035, the annual demand for vectors is expected to grow at an annualized rate of 11%
Currently, North America and Europe contribute to more than 70% of the demand for viral and non-viral vectors. By 2035, the demand, in terms of number of patients in clinical and commercial stage, demand for vectors, is projected to be ~ 400 thousand patients.
   
The market is anticipated to grow at a significant rate, during the period 2022-2035
The majority share of service revenues is anticipated to come from vector manufacturing projects focused on oncological disorders (51%). By 2035, Europe is likely to capture the major share (42%) of the market followed by North America (30%) and Asia-Pacific (23%).

For additional details, please visit link https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html or email sales@rootsanalysis.com

You may also be interested in the following titles:
1.   Targeted protein degradation market, 2022-2035
2.   Cell Therapy Manufacturing Market, 2021-2030
3.   Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
      
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/
Logged
Pages: [1] Go Up Print 
« previous next »
Jump to:  


Login with username, password and session length

Powered by MySQL Powered by PHP Powered by SMF 1.1.12 | SMF © 2006-2009, Simple Machines LLC Valid XHTML 1.0! Valid CSS!

CeriaTone Forum is not afiliated with Ceriatone Amplifications. The CeriaTone and name, logo and related trademarks and service marks, owned by CeriaTone. , are registered and/or used in the U.S. and many foreign countries. All other trademarks, service marks, and trade names referenced in this site are the property of their respective owners.